Asston Pharmaceuticals Ltd (544445)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Asston Pharmaceuticals' revenue was ₹10.1 Cr (+10.8% year on year, -34.8% on the previous half-year), and net profit ₹0.5 Cr (-75.4% year on year); the operating margin was -27.9%.
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹10.1 | +10.8% | -34.8% |
| Operating profit | ₹-2.8 | to loss | to loss |
| Net profit | ₹0.5 | -75.4% | — |
| EPS (₹) | 0.56 | -82.0% | — |
| Operating margin | -27.9% | — | — |
📢 Recent Corporate Announcements
Asston Pharmaceuticals Limited announced that its Board of Directors approved shifting the company's registered office within the local limits of Navi Mumbai. The registered office will move from CBD Belapur to Nerul, Navi Mumbai, effective October 15, 2026. This administrative change falls under the same Registrar of Companies jurisdiction. The meeting took place on October 13, 2026, lasting 20 minutes from 04:00 PM to 04:20 PM.
- Board approved shifting the registered office effective October 15, 2026
- Old office located at Office No. A-431, Balaji Bhavan, 4th Floor, Sector-11 CBD Belapur, Navi Mumbai
- New office located at Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai
- Board meeting commenced at 04.00 P.M. and concluded at 04.20 P.M. on October 13, 2026
Asston Pharmaceuticals Limited announced that its Board of Directors approved shifting the company's registered office within the local limits of Navi Mumbai. The registered office will move from CBD Belapur to Nerul, Navi Mumbai, effective October 15, 2026. This administrative change falls under the same Registrar of Companies jurisdiction. The meeting took place on October 13, 2026, lasting 20 minutes from 04:00 PM to 04:20 PM.
- Board approved shifting the registered office effective October 15, 2026
- Old office located at Office No. A-431, Balaji Bhavan, 4th Floor, Sector-11 CBD Belapur, Navi Mumbai
- New office located at Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai
- Board meeting commenced at 04.00 P.M. and concluded at 04.20 P.M. on October 13, 2026
Asston Pharmaceuticals has scheduled a Board of Directors meeting on October 13, 2026. The board will consider and approve the acquisition of immovable property through a bank or financial institution auction, alongside shifting the company's registered office address. Financial outlays and property details were not disclosed in the intimation. Any significant capex will be evaluated against the company's current net worth of ₹39 crore and debt of ₹5 crore.
- Board meeting scheduled for Tuesday, 13th October, 2026
- Proposal to acquire immovable property via Bank/Financial Institution Auction
- Proposal to shift the registered office address of the company
- Intimation submitted under Regulation 29(1) on 06th October, 2026
Asston Pharmaceuticals announced that shareholders at its 7th Annual General Meeting held on September 29, 2026, approved key corporate resolutions. Mr. Ashish Narayan Sakalkar was re-appointed as Managing Director under retirement by rotation provisions. Additionally, members approved the appointment of M/s Panchal S K & Associates as Statutory Auditors and cleared remuneration increases for the Managing Director, CEO, and a Non-Executive Director. The company posted FY26 revenue of Rs 25.47 crore with a net profit of Rs 3.87 crore.
- Shareholders approved resolutions at the 7th AGM held on September 29, 2026
- Re-appointment of MD Ashish Narayan Sakalkar (DIN: 06601011) retiring by rotation under section 152(6)
- Appointment of M/s Panchal S K & Associates (ICAI Reg. No. 145989W) as Statutory Auditors
- Remuneration increases approved for MD Ashish Sakalkar, CEO Saili Jayaram More, and Non-Executive Director Sachin Badakh
Asston Pharmaceuticals Limited has submitted a regulatory disclosure to the exchange under Regulation 29(1) of SEBI (SAST) Regulations, 2011. The submission follows a disclosure received by the company on August 31, 2026, from Mrs. Prakruti R Pali regarding share acquisition. The specific share volume, transaction price, and resulting ownership percentage were not detailed in the submitted cover letter.
- Disclosure under Regulation 29(1) of SEBI (SAST) Regulations submitted to BSE
- Acquisition disclosure received from Mrs. Prakruti R Pali on 31st August, 2026
- Specific acquisition size and post-transaction shareholding not disclosed in the filing extract
Asston Pharmaceuticals Ltd has scheduled a Board of Directors meeting on September 4, 2026. The agenda includes considering the appointment of M/s Panchal S K & Associates as Statutory Auditor and approving hikes in managerial remuneration for the Managing Director, CEO, and a Non-Executive Director. Additionally, the Board will approve the notice and date for the upcoming 7th Annual General Meeting.
- Board meeting scheduled for Friday, September 4, 2026
- Proposal to appoint M/s Panchal S K & Associates (FRN: 145989W) as Statutory Auditor
- To review and approve remuneration increase for MD Ashish Narayan Sakalkar and WTD & CEO Saili Jayaram More
- To approve remuneration increase for Non-Executive Director Sachin Chandrakant Badakh
- To finalize notice and schedule for convening the 7th Annual General Meeting
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
